Disialoganglioside GD2 (NH4+ salt)

CATALOG # 1527
Amount 500 µg
Price $665.00
Qty
 
Disialoganglioside GD2 (NH4+ salt)
  • Catalog #:1527
  • Scientific Name:Disialoganglioside GD2 (NH4+ salt)
  • Common Name:GD2
  • Empirical Formula:C78H138N4O34•2NH3 (stearoyl) Typical fatty acid content
  • CAS#65988-71-8
  • SDSView Safety Data Sheet
  • Data Sheet:View Data Sheet
  • Formula Weight:1676+2NH3 (stearoyl)
  • Unit:500 µg
  • Source:semisynthetic
  • Purity:98+%
  • Analytical Methods:TLC, MS, identity confirmed by MS
  • Natural Source:rabbit
  • Solubility:chloroform/methanol/DI water, 2:1:0.1; forms micellar solution in water
  • Physical Appearance:solid
  • Storage:-20°C
  • Dry Ice:No
  • Hazardous:No
  • Literature References:Application Notes:

    Gangliosides1 are acidic glycosphingolipids that form lipid rafts in the outer leaflet of the cell plasma membrane, especially in neuronal cells in the central nervous system.2 They participate in cellular proliferation, differentiation, adhesion, signal transduction, cell-to-cell interactions, tumorigenesis, and metastasis. The accumulation of gangliosides has been linked to several diseases including Tay-Sachs and Sandhoff disease and cancer. Disialoganglioside GD2 is normally found mostly in the central nervous system and in low amounts in peripheral nerves and skin melanocytes. However in various cancers aberrant glycosilation produces relatively high amounts of GD2 on tumor cell surfaces and has been shown to enhance tumor proliferation and metastasis. The relatively tumor specific expression of GD2 makes it a good candidate for immunotherapy using anti-GD2 antibodies and this approach has been actively pursued for the past several decades.3,4

    References:
    1. L. Svennerholm, et al. (eds.), Structure and Function of Gangliosides, New York, Plenum, 1980
    2. T. Kolter, R. Proia, K. Sandhoff “Combinatorial Ganglioside Biosynthesis” J. Biol. Chem., Vol. 277:29 pp. 25859-25862, 2002
    3. M. Ahmed and N. Cheung “Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy” FEBBS Lett. Vol. 588 pp. 288-297, 2014
    4. M. Ahmed, J. Hu, and N. Cheung “Structure based refinement of a humanized monoclonal antibody that targets tumor antigen disialoganglioside GD2” Front. Immunol. Vol. 5(372) pp. 1-6, 2014